Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Waldschmidt, D. [1 ]
El-Khoueir, A. B. [2 ]
Kim, R. D. [3 ]
Harris, W. P. [4 ]
Sung, M. W. [5 ]
Iqbal, S. [2 ]
Zhang, A. [6 ]
Nakajima, K. [6 ]
Galle, P. R. [7 ]
机构：
[1] Univ Klin Koln, Klin Gastroenterol & Hepatol, Cologne, Germany
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Tisch Canc Inst Mt Sinai, New York, NY USA
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Univ Med Ctr Mainz, Mainz, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
153
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Karwal, Mark
    Verslype, Chris
    Van Vlierberghe, Hans
    Kardosh, Adel
    Zagonel, Vittorina
    Stal, Per
    Sarker, Debashis
    Palmer, Daniel H.
    Vogel, Arndt
    Edeline, Julien
    Cattan, Stephane
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Chisamore, Michael Jon
    Wang Anran
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Albiges, L.
    Gurney, H. P.
    Atduev, V.
    Suarez, C.
    Climent Duran, M. A.
    Pook, D.
    Tomczak, P.
    Barthelemy, P.
    Lee, J-L.
    Nalbandian, T.
    Stus, V.
    Ferguson, T.
    Wiechno, P.
    Gokmen, E.
    Lacombe, L.
    Gedye, C.
    Perini, R.
    Sharma, M.
    Li, C.
    Lee, C-H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [33] Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma
    Jia, F.
    Ren, Z.
    Xu, J.
    Shao, G.
    Dai, G.
    Liu, B.
    Xu, A.
    Yang, Y.
    Wang, Y.
    Zhou, H.
    Chen, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S692 - S692
  • [34] Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
    Kudo, Masatoshi
    Motomura, Kenta
    Wada, Yoshiyuki
    Inaba, Yoshitaka
    Sakamoto, Yasunari
    Kurosaki, Masayuki
    Umeyama, Yoshiko
    Kamei, Yoichi
    Yoshimitsu, Junichiro
    Fujii, Yosuke
    Aizawa, Mana
    Robbins, Paul B.
    Furuse, Junji
    LIVER CANCER, 2021, 10 (03) : 249 - 259
  • [35] A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
    Kudo, Masatoshi
    Finn, Richard S.
    Ikeda, Masafumi
    Sung, Max W.
    Baron, Ari D.
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Meyer, Tim
    Nagao, Satoshi
    Saito, Kenichi
    Mody, Kalgi
    Ramji, Zahra
    Dubrovsky, Leonid
    Llovet, Josep M.
    LIVER CANCER, 2024, 13 (04)
  • [36] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
    Zhu, Andrew X.
    Finn, Richard S.
    Ikeda, Masafumi
    Sung, Max W.
    Baron, Ari David
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma
    Ribas, A.
    Hodi, F. S.
    Lawrence, D.
    Atkinson, V.
    Agarwal, S.
    Carlino, M. S.
    Fisher, R.
    Long, G. V.
    Miller, W. H.
    Huang, Y.
    Moreno, B. Homet
    Ibrahim, N.
    Hamid, O.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [39] Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
    Borad, Mitesh J.
    Bai, Li-Yuan
    Richards, Donald
    Mody, Kabir
    Hubbard, Joleen
    Rha, Sun Young
    Soong, John
    McCormick, Daniel
    Tse, Emmett
    O'Brien, Daniel
    Bayat, Ahmad
    Ahn, Daniel
    Davis, S. Lindsey
    Park, Joon Oh
    Oh, Do-Youn
    HEPATOLOGY, 2023, 77 (03) : 760 - 773
  • [40] Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
    Qin, S.
    Finn, R. S.
    Kudo, M.
    Meyer, T.
    Vogel, A.
    Ducreux, M. P.
    Macarulla, T. M.
    Tomasello, G.
    Boisserie, F.
    Hou, J.
    Li, C.
    Song, J.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2018, 29
12345